Hydroxychloroquine Dosage Calculator

About the Hydroxychloroquine Dosage Calculator

Hydroxychloroquine (HCQ, brand name Plaquenil) is a commonly used therapy for systemic lupus erythematosus and rheumatoid arthritis. Long-term use carries a risk of irreversible retinal toxicity (hydroxychloroquine retinopathy) that is related to cumulative exposure and daily dose relative to body weight. The American Academy of Ophthalmology (AAO) recommendations commonly use a 5 mg/kg/day actual-body-weight ceiling as the key safety reference, replacing the older ideal-body-weight rule.

This worksheet compares the AAO dose ceiling against actual body weight, computes ideal body weight using the Devine formula for comparison, summarizes retinal toxicity risk factors, and provides the AAO ophthalmologic screening schedule used on this page. For patients whose calculated maximum dose falls between the available 200 mg tablet sizes, it suggests alternating-day dosing schedules.

Understanding hydroxychloroquine dosing is critical because retinal toxicity prevalence increases dramatically after 5 years of use — from less than 1% in the first 5 years to up to 20% after 20 years at doses exceeding 5 mg/kg/day. Once hydroxychloroquine retinopathy is detected, it is irreversible and may progress even after drug discontinuation, making prevention through proper dosing the primary strategy.

When This Page Helps

Hydroxychloroquine retinopathy is irreversible, making correct dosing the primary prevention strategy. This calculator ensures doses stay within the AAO-recommended ≤ 5 mg/kg/day limit, calculates ideal body weight for comparison, assesses cumulative retinal toxicity risk across five factors, and provides the appropriate ophthalmologic screening schedule — critical information often overlooked in routine prescribing.

How to Use the Inputs

1. Enter the patient's actual body weight in kg or lb.
2. Enter height and select sex to calculate ideal body weight using the Devine formula.
3. Choose the clinical indication from the dropdown.
4. Enter the number of years the patient has been on hydroxychloroquine (0 if starting).
5. Indicate whether the patient has renal disease or pre-existing macular disease.
6. Review the recommended dose, maximum safe dose, and retinal toxicity risk assessment.
7. Follow the AAO screening schedule recommendations displayed.

Example Calculation

Tips & Best Practices

• The 5 mg/kg/day limit is based on ACTUAL body weight in the AAO framework summarized on this page.
• Most patients do well on 200–400 mg/day; reassess need for the full 400 mg in patients under 80 kg.
• Hydroxychloroquine takes 3–6 months to reach full therapeutic effect — set patient expectations.
• Ensure every patient on HCQ > 5 years has annual OCT + 10-2 visual field testing.
• If retinopathy is detected, HCQ should be stopped immediately — but damage may still progress.
• Counsel patients to report any changes in central vision, color vision, or reading ability immediately.

AAO Guidance Update

The American Academy of Ophthalmology guidance made several important changes to hydroxychloroquine screening and dosing recommendations. The maximum daily dose was reduced from 6.5 mg/kg of ideal body weight to 5 mg/kg of actual body weight, reflecting newer data showing that retinal toxicity risk is better predicted by actual weight-based dosing. The use of multifocal ERG was deemphasized in favor of spectral-domain OCT as the primary screening tool, with 10-2 visual field testing as a complementary modality. The recommendation for baseline eye exam within the first year was maintained, with annual screening starting after 5 years for low-risk patients.

Retinal Toxicity Mechanism

Hydroxychloroquine accumulates in the retinal pigment epithelium (RPE) and is slowly released over months to years, even after drug discontinuation. The exact mechanism involves inhibition of lysosomal function in RPE cells, accumulation of lipofuscin-like material, and eventual photoreceptor cell death. The characteristic "bull's eye" maculopathy pattern results from this parafoveal photoreceptor loss. Asian patients may present with a more peripheral distribution of retinal damage, making standard 10-2 visual field testing less sensitive — wider field testing (24-2 or 30-2) may be warranted.

Long-Term HCQ Benefits in Lupus

Despite retinal toxicity concerns, the overall benefit-risk ratio of hydroxychloroquine in SLE is strongly positive. HCQ reduces lupus flares by 50%, decreases organ damage accrual, improves survival, reduces thrombotic risk, has favorable effects on lipid profiles, and lowers the risk of neonatal lupus and congenital heart block in pregnancies. Current EULAR guidelines recommend hydroxychloroquine for all SLE patients unless contraindicated, reinforcing the importance of proper dosing to allow long-term safe use.

Frequently Asked Questions

• What is the maximum safe dose of hydroxychloroquine?

  Per the AAO guidance summarized on this page, the maximum safe dose is ≤ 5 mg/kg of actual body weight per day. For most patients, this means ≤ 400 mg/day. The previous 6.5 mg/kg ideal-body-weight rule has been superseded.

• Should I use actual or ideal body weight for dosing?

  The AAO guidance recommends using actual body weight. However, in obese patients, the drug does not distribute proportionally into fat tissue, so some clinicians use the lesser of actual weight or ideal body weight × 1.2 as a conservative approach.

• What is hydroxychloroquine retinopathy?

  HCQ retinopathy is damage to the retinal pigment epithelium and photoreceptors, typically in a "bull's eye" pattern around the macula. It is irreversible and can progress after stopping the drug. Early detection by OCT is critical because advanced retinopathy causes permanent central vision loss.

• When should eye screening start?

  Per AAO guidelines: baseline exam within the first year, then annual screening after 5 years of use. Patients with risk factors (renal disease, high dose, macular disease) should begin annual screening sooner. Screening includes OCT and 10-2 visual field testing.

• How does renal disease affect HCQ dosing?

  Hydroxychloroquine is partially cleared by the kidneys. Decreased renal function leads to drug accumulation, increasing retinal toxicity risk. Patients with significant renal impairment may need dose reduction and should begin ophthalmologic screening earlier than the standard 5-year mark.

• Can hydroxychloroquine be used during pregnancy?

  Yes. Unlike many immunosuppressants, hydroxychloroquine is considered safe during pregnancy and breastfeeding. It is actually recommended to continue HCQ throughout pregnancy in SLE patients, as discontinuation increases flare risk and adverse pregnancy outcomes.